Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Baxter International Inc. (BAX) — XLV Health Care · S&P 500 Profile |百特介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Baxter International Inc. (BAX) — Business, History & S&P 500 Profile |百特介紹

Baxter International company profile · medical products, systems & pharmaceuticals · history · financial snapshot · S&P 500 rank #461 · 百特公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 3, 2026 (frozen benchmark)
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$13.19B
Nov 3, 2026 · Slickcharts (frozen benchmark)
S&P 500 WEIGHT
0.02%
Rank #461 · Nov 3, 2026 (Slickcharts)
FY2025 REVENUE
$11.24B
+5.7% YoY · sales
FY2025 NET LOSS
-$957M
Diluted loss per share -$1.87 · operating loss -$308M

SNAPSHOT

TickerBAX (NYSE)
CompanyBaxter International Inc.
GICS sector / industryHealth Care (XLV) / Health Care Equipment
S&P 500 rank (by weight)#461 · 0.02% (Nov 3, 2026)
Sector rank (by market cap)#52 in Health Care (Nov 3, 2026)
Share price (frozen benchmark)$25.49 (Nov 3, 2026)
HeadquartersDeerfield, Illinois
Founded1931
CEOJosé Almeida (Chair, President and CEO)
EmployeesNot available
Market cap$13.19B (Nov 3, 2026)

WHAT IT DOES

Baxter International makes medical products and therapies used in hospitals and homes — infusion pumps and IV solutions, surgical products, renal care and pharmaceuticals — sold through its Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals segments. FY2025 sales were $11,244M, up 5.7% from $10,636M, and gross profit was $3,379M, a 30.1% margin.

The headline is a second consecutive GAAP loss: operating income was a loss of $308M, versus a profit of $14M in 2024, and net income was a loss of $957M, versus a loss of $649M in 2024, with a diluted loss per share of $1.87 versus $1.27. A quotelinks prose claim of EPS $2.27 contradicts its own table and the Zacks, roic and Fidelity tables and is rejected — the table figure of −$1.87 is used. Sales growth alongside a widening loss says charges, restructuring and portfolio costs, not demand, drive the GAAP line.

Portfolio change frames the comparison: the kidney care business (Vantive) was sold in early 2025, so Baxter's FY2025 perimeter is smaller and more hospital-focused than FY2024's. Segment figures for FY2025 were not verified from the sources used, so the segments are listed qualitatively.

BUSINESS SEGMENTS — FY2025

SegmentRevenueShareYoY
Medical Products and Therapies———
Healthcare Systems and Technologies———
Pharmaceuticals———
Total sales$11,244M100%+5.7%
Segment sales figures for FY2025 were not verified from the sources used, so the table is qualitative. Segment revenue split not stated in the sources used; units are listed qualitatively, with revenue, share and YoY shown as —. Do not read a split from this table.

HISTORY

YearMilestone
1931Donald Baxter founds Baxter Laboratories in Glenview, Illinois, making intravenous solutions
1950Baxter introduces the first flexible plastic IV container, replacing glass bottles
1971Baxter lists publicly, growing into a global hospital supplier
2015Baxter spins off Baxalta, its biopharmaceutical business, focusing on medical products
2025Baxter sells its kidney care business (Vantive) in early 2025; FY2025 sales reach $11,244M with a net loss of $957M

COMPETITIVE POSITION

  • Hospital installed base — infusion pumps and IV solutions are in nearly every US hospital, giving Baxter recurring consumable sales tied to hospital volumes.
  • Portfolio focus — the Vantive sale sharpens Baxter on hospital products and pharmaceuticals, but removes a growth leg and shrinks the revenue base.
  • Restructuring burden — two consecutive GAAP loss years show the cost of reshaping the portfolio; the question is whether the remaining business earns its cost of capital.
  • Quality and recall risk — medical-device manufacturing is regulated and recall-prone; a major recall can cut supply and revenue for quarters.
  • Competition — Becton Dickinson, Medtronic, Fresenius and ICU Medical contest infusion, surgical and renal markets, and hospital group purchasing organizations press prices.

FINANCIAL SNAPSHOT — FY2025

Sales$11,244M (+5.7% YoY)
Gross profit$3,379M (30.1% margin)
Operating income (loss)-$308M (vs +$14M in FY2024)
Net income (loss)-$957M (vs -$649M in FY2024)
Diluted loss per share-$1.87 (vs -$1.27 in FY2024)
Source: Baxter International FY2025 Form 10-K, filed Feb 12, 2026. A quotelinks prose claim of EPS $2.27 contradicts its own table and the Zacks, roic and Fidelity tables and is rejected; the table figure of −$1.87 is used. Segment figures for FY2025 were not verified and are listed qualitatively. The Vantive (kidney care) sale in early 2025 changes the comparison perimeter.

KEY RISKS

  • Loss persistence — two consecutive GAAP loss years raise the question of whether the reshaped Baxter can return to sustained profitability.
  • Recall and supply risk — device recalls or plant disruptions can cut hospital supply and trigger regulatory action.
  • Hospital budget pressure — group purchasing organizations and hospital cost control press device and consumable prices.
  • Portfolio execution — the Vantive sale's proceeds and the remaining portfolio's focus must now deliver growth that the old perimeter did not.
  • Tariff and input costs — resins, electronics and logistics costs move with trade policy and energy prices.

WHY IT MATTERS FOR THE S&P 500

Baxter International is the S&P 500's hospital-supply name: at a 0.02% index weight and Health Care #52, it is the index's main exposure to the infusion pumps, IV solutions and surgical products that every hospital runs on.

Its sales-growth-versus-loss split is a standing read on medical-device restructuring — $11,244M of sales growing 5.7% while the GAAP line loses $957M says the story is portfolio cost, not hospital demand.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Nov 3, 2026 close) and Slickcharts S&P 500 analysis page (market cap)
FinancialsBaxter International FY2025 Form 10-K, filed Feb 12, 2026 (fiscal year ended Dec 31, 2025)
Sector classificationGICS (Health Care Equipment) via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

BAX

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

代碼BAX(NYSE)
公司Baxter International Inc.
GICS 板塊/行業醫療保健(XLV)/醫療保健設備
標普500排名(按權重)#461 · 0.02%(2026 年 11 月 3 日)
板塊內排名(按市值)醫療保健第 #52(2026 年 11 月 3 日)
股價(凍結基準)$25.49(2026 年 11 月 3 日)
總部美國伊利諾伊州迪爾菲爾德
成立1931 年
行政總裁José Almeida(董事長、總裁兼行政總裁)
員工Not available
市值$13.19B(2026 年 11 月 3 日)

業務概覽

Baxter International 製造醫院與家庭使用的醫療產品與療法——輸液泵與靜脈輸液、外科產品、腎臟護理與藥品——通過醫療產品與療法、醫療保健系統與技術、藥品三大板塊銷售。FY2025 銷售額為 $11,244M,較 $10,636M 增長 5.7%;毛利為 $3,379M,利潤率 30.1%。

標題是一連第二年的 GAAP 虧損:營業利潤為虧損 $308M,對比 2024 年盈利 $14M;淨利潤為虧損 $957M,對比 2024 年虧損 $649M;攤薄每股虧損為 $1.87,對比 $1.27。quotelinks 正文聲稱每股盈利 $2.27,與其自身表格及 Zacks、roic 與 Fidelity 表格相矛盾,予以拒絕——採用表格數字 −$1.87。銷售增長而虧損擴大,說明撥備、重組與組合成本、而非需求,驅動 GAAP 數字。

組合變化框定比較:腎臟護理業務(Vantive)於 2025 年初出售,故 Baxter 的 FY2025 範圍較 FY2024 更小、更聚焦醫院。FY2025 板塊數字未自所用來源核實,故板塊只作定性列示。

業務板塊 — FY2025

板塊收入佔比同比
醫療產品與療法———
醫療保健系統與技術———
藥品———
銷售額合計$11,244M100%+5.7%
FY2025 板塊銷售數字未自所用來源核實,故本表只作定性列示。 板塊收入拆分未見於所用來源;本表只作定性列示,收入、佔比與同比均記為 —,請勿據此推斷拆分。

歷史沿革

年份里程碑
1931Donald Baxter 在伊利諾伊州格倫維尤創立 Baxter Laboratories,生產靜脈輸液
1950Baxter 推出首款柔性塑料靜脈輸液容器,取代玻璃瓶
1971Baxter 公開上市,成長為全球醫院供應商
2015Baxter 分拆 Baxalta 生物製藥業務,聚焦醫療產品
2025Baxter 於 2025 年初出售腎臟護理業務(Vantive);FY2025 銷售額達 $11,244M,淨虧損 $957M

競爭地位

  • 醫院裝機基礎——輸液泵與靜脈輸液遍佈幾乎每家美國醫院,令 Baxter 擁有與醫院診量掛鈎的經常性耗材銷售。
  • 組合聚焦——Vantive 出售令 Baxter 聚焦醫院產品與藥品,但移除一條增長腿並縮小收入基礎。
  • 重組負擔——連續兩年 GAAP 虧損顯示重塑組合的成本;問題在於餘下業務能否賺取資本成本。
  • 品質與召回風險——醫療器械製造受監管且易召回;重大召回可削減供應與收入數季。
  • 競爭——Becton Dickinson、Medtronic、Fresenius 與 ICU Medical 爭奪輸液、外科與腎臟市場,醫院集團採購組織壓低價格。

財務快照 — FY2025

銷售額$11,244M(同比 +5.7%)
毛利$3,379M(利潤率 30.1%)
營業利潤(虧損)−$308M(FY2024 為 +$14M)
淨利潤(虧損)−$957M(FY2024 為 −$649M)
攤薄每股虧損−$1.87(FY2024 為 −$1.27)
來源:Baxter International FY2025 Form 10-K,於 2026 年 2 月 12 日申報。quotelinks 正文聲稱每股盈利 $2.27,與其自身表格及 Zacks、roic 與 Fidelity 表格相矛盾,予以拒絕;採用表格數字 −$1.87。FY2025 板塊數字未獲核實,只作定性列示。Vantive(腎臟護理)於 2025 年初出售,改變比較範圍。

主要風險

  • 虧損持續——連續兩年 GAAP 虧損,令人質疑重塑後的 Baxter 能否恢復持續盈利。
  • 召回與供應風險——器械召回或工廠中斷可削減醫院供應並觸發監管行動。
  • 醫院預算壓力——集團採購組織與醫院成本控制壓低器械與耗材價格。
  • 組合執行——Vantive 出售所得與餘下組合的聚焦,現須交付舊範圍未能交付的增長。
  • 關稅與投入成本——樹脂、電子元件與物流成本隨貿易政策與能源價格變動。

對標普500的重要性

Baxter International 是標普500的醫院供應股:指數權重 0.02%、醫療保健第 #52,是指數對每家醫院都運行的輸液泵、靜脈輸液與外科產品的主要敞口。

其銷售增長與虧損的分裂,是醫療器械重組的常設讀數——$11,244M 銷售額增長 5.7% 而 GAAP 數字虧損 $957M,說明故事是組合成本,而非醫院需求。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 3 日收盤)及 Slickcharts 標普500分析頁(市值)
財務Baxter International FY2025 Form 10-K,於 2026 年 2 月 12 日申報(財政年度截至 2025 年 12 月 31 日)
板塊分類GICS(醫療保健設備),據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

BAX

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · BAX
Data as of Nov 3, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · Pinnacle West Capital Corporation (PNW) — XLU Utilities · S&P 500 Profile |巔峰西部介紹Next · Brown-Forman Corporation (BF.B) — XLP Consumer Staples · S&P 500 Profile |布朗福曼介紹

Entered 2026-11-04 06:17 · updated 2026-11-14 22:59 · rev 5